Follow-On Biologics Bill’s Prospects Are Uncertain, Waxman Staffer Says

Busy House committee schedule and “fractured” Senate will make reaching consensus a challenge, Ann Witt says, but potential inclusion of FOBs into health reform bill is “wildcard.”